Dantrolene
Systematic (IUPAC) name
1-{[5-(4-nitrophenyl)-2-furyl]methylideneamino} imidazolidine-2,4-dione
Identifiers
CAS number	7261-97-4
ATC code	M03CA01
PubChem	2952
DrugBank	APRD00901
ChemSpider	2847
Chemical data
Formula	C14H10N4O5
Mol. mass	314.253 g/mol
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	70%
Metabolism	Liver
Half life	?
Excretion	Biliary, renal
Therapeutic considerations
Pregnancy cat.	C(US)
Legal status
Routes	Oral, intravenous
Y(what is this?)  (verify)

Dantrolene sodium is a muscle relaxant that acts by abolishing excitation-contraction coupling in muscle cells, probably by action on the ryanodine receptor. It is the only specific and effective treatment for malignant hyperthermia, a rare, life-threatening disorder triggered by general anesthesia. It is also used in the management of neuroleptic malignant syndrome, muscle spasticity (e.g. after strokes, in paraplegia, cerebral palsy, or patients with multiple sclerosis), ecstasy intoxication, serotonin syndrome, and 2,4-dinitrophenol poisoning.^[1] It is marketed by JHP Pharmaceuticals LLC as Dantrium (in North America) and Dantrolen (Europe).

[edit] History

Dantrolene was first described in the scientific literature in 1967, as one of several hydantoin derivatives proposed as a new class of muscle relaxant.^[2] Dantrolene underwent extensive further development, and its action on skeletal muscle was described in detail in 1973.^[3]

Dantrolene was widely used in the management of spasticity before its efficacy in treating malignant hyperthermia was discovered by South African anesthesiologist Gaisford Harrison and reported in a landmark 1975 article published in the British Journal of Anaesthesia.^[4] Harrison experimentally induced malignant hyperthermia with halothane anesthesia in genetically susceptible pigs, and obtained a 87.5% survival rate, where seven of his eight experiments survived after intravenous administration of dantrolene; only one animal died during the course of the study. The efficacy of dantrolene in humans was later confirmed in a large, multicenter study published in 1982.^[5] Before dantrolene, the only available treatment for malignant hyperthermia was procaine, which was associated with a 60% mortality rate in animal models.^[4]

[edit] Contraindications

Dantrolene cannot be used in people with:^{[citation needed]}

• preexisting liver disease
• compromised lung function
• severe cardiovascular impairment
• known hypersensitivity to dantrolene
• pediatric patients under 5 years of age
• whenever good muscular balance/strength is needed to maintain an upright position, motoric function, or proper neuromuscular balance

If the indication is a medical emergency such as malignant hyperthermia, the only significant contraindication is hypersensitivity.^{[citation needed]}

[edit] Pregnancy and breastfeeding

If needed in pregnancy, adequate human studies are lacking, therefore the drug should be given in pregnant women only if clearly indicated. It may cause hypotonia in the newborn if given closely before delivery.^[1]

Dantrolene should not be given to breastfeeding mothers. If a treatment is necessary, breastfeeding should be terminated.^{[citation needed]}

[edit] Adverse effects

Central nervous system side effects are quite frequently noted and encompass speech and visual disturbances, mental depression and confusion, hallucinations, headache, insomnia and exacerbation or precipitation of seizures, and increased nervousness. Infrequent cases of respiratory depression or a feeling of suffocation have been observed. Dantrolene often causes sedation severe enough to incapacitate the patient to drive or operate machinery.

Gastrointestinal effects include bad taste, anorexia, nausea, vomiting, abdominal cramps, and diarrhea.

Hepatic side effects may be seen either as asymptomatic elevation of liver enzymes and/or bilirubin or, most severe, as fatal and nonfatal hepatitis. The risk of hepatitis is associated with the duration of treatment and the daily dose. In patients treated for hyperthermia, no liver toxicity has been observed so far.

Pleural effusion with pericarditis (oral treatment only), rare cases of bone marrow damage, diffuse myalgias, backache, dermatologic reactions, transient cardiovascular reactions, and crystalluria have additionally been seen. Muscle weakness may persist for several days following treatment.

[edit] Mutagenicity and carcinogenity

Dantrolene gave positive results in animal high dose studies (with and without enzymatic activation) regarding mutagenicity and carcinogenity. No evidence for human mutagenicity and carcinogenity has been found during the long years of clinical experience.^{[citation needed]}

[edit] Method of action

Dantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor, and decreasing intracellular calcium concentration.^[1]

[edit] Chemistry

Skeletal formula of azumolene. The bromine atom replacing the nitro group found in dantrolene may be seen at left.

Chemically it is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.^[1]

The poor water solubility of dantrolene leads to certain difficulties in its use.^[1][6] A more water-soluble analog of dantrolene, azumolene, is under development for similar indications.^[6] Azumolene has a bromine residue instead of the nitro group found in dantrolene, and is 30 times more water-soluble.^[1]

[edit] Drug interactions

Dantrolene may interact with the following drugs:^[7]

• Calcium channel blockers of the diltiazem/verapamil type: Intravenous treatment with dantrolene and concomitant calcium channel blocker treatment may lead to severe cardiovascular collapse, arrhythmias, myocardial depressions, and hyperkalemia.
• Non-depolarizing neuromuscular blocking agents, such as vecuronium bromide: Neuromuscular blockade is potentiated.
• CNS depressants: Sedative action is potentiated. Benzodiazepines may also cause additive muscle weakness.
• Combined oral contraceptives and hormone replacement therapy with estrogens: May enhance liver toxicity of dantrolene, particularly in women over 35 years of age.

[edit] References

[edit] External links

• http://www.kompendium.ch/MonographieTxt.aspx?lang=de&MonType=fi Swiss Drug Compendium on oral Dantrolene (German)